source
- Emerging biotech hubs like India could help lower global drug costs by scaling developmentThe article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…
- Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concernsNovartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…